Business Wire

GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Share

GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006355/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GE HealthCare is innovating in contrast media (Photo: Business Wire)

The macrocyclic, extra-cellular – or general-purpose – manganese-based contrast agent has comparable relaxivity - the ability of a contrast agent to enhance signal intensity during an MRI scan - and is expected to be diagnostically similar to current gadolinium-based contrast agents (GBCAs). Unlike gadolinium, manganese is endogenous, meaning that it is a trace element that is naturally occurring in and efficiently eliminated from the body. Along with its magnetic properties, this makes a manganese-based agent a viable alternative to gadolinium. In addition, a non-gadolinium agent could help limit the potential impact of post-patient excreted gadolinium in the environment.

The clinical trial, based at the clinical research unit at the Oslo University Hospital, Rikshospitalet, Norway, and overseen by Lead Investigator, Hasse K. Zaré, aims to investigate the safety profile and how this injectable manganese contrast agent is eliminated from the body in healthy volunteers. Previous manganese-based MRI agents have been reliant on a ‘free manganese’ release mechanism for their imaging efficacy. This novel investigational agent is tightly bound to the chelate, in a macrocyclic cage-like structure, so it is rapidly eliminated from - rather than actively released into - the body.

Dr Paul Evans, Head of Global R&D at GE HealthCare’s Pharmaceutical Diagnostics unit, said: “For many years we’ve been committed to investing in, and bringing to market, products to help solve some of radiology’s biggest challenges and unmet needs. This manganese-based MRI agent is one of a number of novel agents we have at various stages of development in our innovation pipeline, all of which aim to give practitioners more choice in delivering precision care for their patients.”

GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE imaging agents have been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.

Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

GE HealthCare Media:
Mathilde Bouscaillou
M +3364 700 8271
Mathilde.Bouscaillou@ge.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health7.6.2023 14:30:00 EEST | Press release

Today, Organon (NYSE:OGN), a global healthcare company focused on women’s health, and CAF, Development Bank of Latin America, signed a memorandum of understanding (MOU) to contribute to the United Nations Sustainable Development Goals through the design, structure and implementation of sustainable programs that promote and improve equity, health and autonomy of girls and women in Latin America and the Caribbean. Across the globe, tremendous gaps exist in women’s health that can potentially prevent women and thus economies from achieving their full potential. Sustainable financing can advance progress in women’s health by mobilizing capital towards initiatives that might not otherwise receive adequate support like increasing access to sexual and reproductive health education and healthcare services. Sustainable financing is one potential solution to address constrained government budgets while catalyzing healthcarei and socioeconomic progress. Health-focused social impact investments –

Falcon 40B: World’s Top AI Model Rewards Most Creative Use Cases in Call for Proposals with Training Compute Power7.6.2023 13:21:00 EEST | Press release

Falcon 40B, the world’s top-ranked open-source AI model on the Hugging Face leaderboard for large language models (LLMs), is registering an overwhelming response to a Call for Proposals from scientists, researchers, and SME entrepreneurs keen to deploy the model for innovative use cases. The response follows back-to-back announcements from the AI model’s creator, Abu Dhabi’s Technology Innovation Institute (TII), offering the most exceptional project ideas access to training compute power as a form of investment. Compute power enables developers to tackle more complex and resource-intensive use cases with increased efficiency, productivity, and performance. By being able to experiment with the capabilities of Falcon 40B, the best open-source LLM globally, developers can venture into uncharted territories, driving innovation and expanding the possibilities of AI solutions - at speed. Submissions are being welcomed from all over the world, and across all industries and sectors to find th

ees Europe 2023: Major Progress in New Battery Technologies7.6.2023 13:07:00 EEST | Press release

More and more electricity is being generated from renewable energies while the electromobility business is growing. Whether we are talking about sustainable power generation or electric mobility, one thing is key: Energy storage – especially battery storage. Manufacturers today primarily rely on lithium-based batteries. But now they are going one step further: The production of batteries is to become more environmentally friendly and the products more efficient, safer and cheaper. To this end, several manufacturers are now looking for alternatives – and they have found them. At ees Europe, the continent’s largest and most international exhibition for batteries and energy storage systems and the concurrent exhibitions, more than 950 suppliers will be presenting their latest products and solutions for the energy storage of the future. What’s more, attendees at the ees Europe Conference will learn first-hand where lithium-based batteries will continue to play out their advantages, but als

Samsung’s Exynos Auto V920 to Power Hyundai Motor’s Next-Generation In-Vehicle Infotainment Systems7.6.2023 13:00:00 EEST | Press release

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that its latest automotive processor, the Exynos Auto V920, has been selected to power Hyundai Motor Company’s next-generation in-vehicle infotainment (IVI) systems, which are expected to roll out by 2025. This marks Samsung’s first collaboration on automotive semiconductors with Hyundai Motor, a global mobility leader. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005489/en/ Samsung Exynos Auto V920 (Graphic: Business Wire) “We are thrilled to be collaborating with Hyundai Motor, a prominent global mobility manufacturer, and we anticipate that this partnership will further solidify our position in the automotive infotainment space,” said Jae Geol Pyee, Executive Vice President of Sales & Marketing, System LSI Business at Samsung Electronics. "Through close collaboration with our global customers and ecosystem partners,

HCLTech Launches Advanced Testing Facility for 5G Infrastructure OEMs7.6.2023 11:44:00 EEST | Press release

HCLTech, a leading global technology company, announced the launch of a state-of-the-art test lab in Chennai, India to enable global telecom infrastructure original equipment manufacturers (OEMs) to test and validate 5G solutions. The facility, which is first of its kind in India, is equipped with high-end scanners that enable global OEMs to test large cellular base stations as well as small form factor antennas used in mobile phones, smart gadgets, health monitoring systems and remote surveillance systems. “We’re committed to advancing next-gen mobile telephony with the highest levels of quality, performance and technology. We have a team of highly experienced and skilled engineers to test and verify cellular and non-cellular products with great precision,” said Vijay Guntur, President, Engineering and R&D Services, HCLTech. Currently equipped to test and validate 5G telecom antennas for frequency bands up to 7 GHz, the lab is scalable to test millimeter-wave frequency 5G infrastructu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom